ClinicalTrials.gg
RecruitingNCT06726642CHARM2Updated Oct 8, 2026

CfDNA in Hereditary And High-risk Malignancies 2

An observational study in Hereditary Cancer Syndrome, sponsored by University Health Network, Toronto. Recruiting at 8 sites in Canada. Open to participants aged Up to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by University Health Network, Toronto · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Oct 8, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,000
Ages
Up to 90 Years
Sex
All
01

Study summary

The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes. If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer detection. The study will compare cancer detection rates between those receiving the new blood test and those receiving standard care, assess if the test leads to earlier cancer diagnosis, and evaluate its impact on patient outcomes. The study will also use questionnaires and interviews to understand how patients feel about the blood test, its incorporation into routine medical care, and perceptions of the medical value of test results. This research could lead to more effective and less invasive cancer screening for high-risk individuals.

Read the detailed description

Through the CHARM Consortium (www.charmconsortium.ca), the investigators have shown that cell-free DNA (cfDNA) profiling can enable more frequent cancer surveillance from readily accessible blood collections. The investigators are now conducting a prospective, multi-center, randomized control trial of cfDNA testing of 1,000 HCS carriers from across Canada to 1) compare cancer detection rates with and without cfDNA testing, 2) assess cancer stage shift and clinical impact reducing mortality and morbidity cancers, and 3) assess impact of access to cfDNA results on patients' quality of life and psychological distress.

02

Conditions studied

  • Hereditary Cancer Syndrome

Keywords

  • cfDNA
  • cell-free DNA
  • Hereditary cancer syndrome
  • BRCA1
  • BRCA2
  • Lynch Syndrome
  • Hereditary breast and ovarian cancer (HBOC)
  • Liquid biopsy
  • Circulating tumor DNA
  • Hereditary Diffuse Gastric Cancer (HDGC)
  • Li-Fraumeni syndrome
03

In context

Neoplastic Syndromes, Hereditary

47 studies on the registry are indexed under Neoplastic Syndromes, Hereditary; 26 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 667 across 24 observational studies indexed under Neoplastic Syndromes, Hereditary.

Browse Neoplastic Syndromes, Hereditary studies →

Lead sponsor

University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The population to be studied includes:

Any individual that underwent clinical genetic testing for hereditary breast and ovarian cancer syndrome, Lynch Syndrome, Neurofibromatosis Type 1, Li-Fraumeni Syndrome or Hereditary Diffuse Gastric Cancer, and was found to carry a detectable variant that is likely pathogenic or pathogenic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a confirmed diagnosis of hereditary breast and ovarian cancer (HBOC), Lynch Syndrome (LS), Neurofibromatosis type I (NF1), Li-Fraumeni Syndrome (LFS), PALB2, and Hereditary Diffuse Gastric Cancer (HDGC), (i.e., patients with an identified pathogenic variant in the respective cancer predisposition gene, or patients with uninformative genetic testing but with a family history suggestive of the cancer predisposition syndrome).
  • Patients must be receiving standard-of-care clinical assessment for cancer by a managing physician under a provincial screening program or cancer surveillance protocol.
  • All patients must have signed and dated an form for this study.

Exclusion criteria

Exclusion Criteria:

  • Patients must not have a personal history of cancer diagnosed and treated within 3 years prior to the expected first sample collection date for this study. If a patient has a personal history of cancer, treatment must have been completed successfully at least 3 years prior to first study sample collection.
  • Patients diagnosed more than 3 years prior to the expected first sample collection date, but never been treated for the cancer.
  • Patients undergoing investigations for a clinical suspicion of cancer.
  • Patients who are not able to comply with the protocol (i.e., tri-annual blood sample collection if randomized into the experimental cohort).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Test cohort

    All participants in the experimental cohort will provide blood samples tri-annually (every 4 months) for 4 years, either at the study hospital or at a local blood laboratory (e.g., LifeLabs). Whenever possible, patients will have research blood collected at the same time as routine blood collections for clinical purposes to avoid additional venipunctures. The samples will undergo cfDNA analysis and all results will be returned to participants by the study team. Participants who receive a "positive" cfDNA assay result will be offered follow-up diagnostic procedures to confirm or rule out the presence of a malignancy. Participants will also complete questionnaires and semi-structured interviews to explore their experience with cfDNA testing and understand perceptions of the clinical utility of cfDNA tests for HCS management.

    Diagnostic Test: Cell-free DNA analysis

  • Control

    Participants in the control cohort will not receive the cfDNA blood test and will continue to receive standard-of-care cancer surveillance according to current guidelines, as they were prior to study enrollment. Participants will complete questionnaires and semi-structured interviews to explore their experience with cfDNA testing and to understand their perception of the clinical utility of cfDNA tests for HCS management.

Interventions

  • Diagnostic testCell-free DNA analysis

    Analysis of cell-free DNA in blood plasma will involve targeted sequencing of key cancer-related genes, cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), and shallow whole genome sequencing (sWGS).

06

What researchers measure

Primary outcomes

  1. Determine the cancer detection rate of the cfDNA sequencing assay in patients with HCS.

    The investigators will assess the performance of the cfDNA assay for cancer detection in patients with HCS, including assay sensitivity, specificity, positive predictive value (PPV,) and negative predictive value (NPV). The test performance endpoint is a diagnosis of cancer and will be assessed at multiple points during the study (at a minimum yearly).

    Time frame: 4 years from enrollment in the study.

Secondary outcomes

  1. To assess the time to cancer diagnosis using cfDNA sequencing compared to controls.

    The investigators will establish whether blood plasma cfDNA testing can detect cancers at the same time as, or earlier, than conventional standard-of-care screening tests for carriers of HCS. The investigators will also assess the time to disease management in carriers receiving cfDNA sequencing results compared to controls.

    Time frame: 4 years from enrollment in the study.

  2. To assess the detection rate of cancers with no standard-of-care screening available using cfDNA sequencing.

    To establish whether cfDNA testing increases the frequency of cancers detected, in particular cancer types with limited detection rates using standard-of-care (e.g., pancreatic cancer, endometrial cancer).

    Time frame: 4 years from enrollment in the study.

  3. Assess the impact of tri-annual cfDNA testing on participant cancer worry.

    The investigators will assess the impact of tri-annual cfDNA testing on participants' cancer related worry, using the Cancer Worry Scale (PMID: 19382100).

    Time frame: 4 years from enrollment in the study.

  4. Assess the impact of tri-annual cfDNA testing on cancer risk perception.

    The investigators will assess the impact of tri-annual cfDNA testing on participants' risk perception, using the Multidimensional Impact of Cancer Risk Assessment (PMID: 12433008).

    Time frame: 4 years from enrollment in the study.

  5. Assess the impact of tri-annual cfDNA testing on cancer anxiety and depression.

    The investigators will assess the impact of tri-annual cfDNA testing on participants' anxiety and depression using the Hospital Anxiety and Depression Scale (PMID: 18325093).

    Time frame: 4 years from enrollment in the study.

07

Study locations

7 of 8 sites recruiting
08

References and documents

Publications

  • Farncombe KM, Wong D, Norman ML, Oldfield LE, Sobotka JA, Basik M, Bombard Y, Carile V, Dawson L, Foulkes WD, Malkin D, Karsan A, Parkin P, Penney LS, Pollett A, Schrader KA, Pugh TJ, Kim RH; CHARM consortium. Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy. Am J Hum Genet. 2023 Oct 5;110(10):1616-1627. doi: 10.1016/j.ajhg.2023.08.014. PubMed 37802042 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2029, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2024
First posted
Dec 10, 2024
StartActual
Apr 19, 2024
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2031
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. 4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • BC Cancer Agency · Vancouver, CanadaNot yet recruiting→Recruiting
  • IWK Health Centre · Halifax, CanadaNot yet recruiting→Recruiting
  • The Hospital for Sick Children · Toronto, CanadaNot yet recruiting→Recruiting
  • Jewish General Hospital · Montreal, CanadaNot yet recruiting→Recruiting
Show site
  • Newfoundland and Labrador Health Services (previously Eastern Health) · St. John's, Canada
Show 1 removed
  • Eastern Health · St. John's, Canada
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The Hospital for Sick Children · Toronto, CanadaContact a•••@sickkids.ca · •••8204→d•••@sickkids.ca · •••5348Contact removed d•••@sickkids.ca · •••5348
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    1 site added, 1 site removed. 4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • BC Cancer Agency · Vancouver, CanadaNot yet recruiting→Recruiting
    • IWK Health Centre · Halifax, CanadaNot yet recruiting→Recruiting
    • The Hospital for Sick Children · Toronto, CanadaNot yet recruiting→Recruiting
    • Jewish General Hospital · Montreal, CanadaNot yet recruiting→Recruiting
    Show site
    • Newfoundland and Labrador Health Services (previously Eastern Health) · St. John's, Canada
    Show 1 removed
    • Eastern Health · St. John's, Canada
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The Hospital for Sick Children · Toronto, CanadaContact a•••@sickkids.ca · •••8204→d•••@sickkids.ca · •••5348Contact removed d•••@sickkids.ca · •••5348
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06726642
Collaborators
British Columbia Cancer Agency, IWK Health Centre, Jewish General Hospital, Sinai Health System, The Hospital for Sick Children, University of Alberta, Women's College Hospital, Eastern Health
Responsible party
Sponsor
First posted
Dec 10, 2024
Start date
Apr 19, 2024
Primary completion
Dec 2029 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 8, 2026

Study contacts

Julia Sobotka, MSc
Contact
charm@uhn.ca
416-409-1387
Raymond Kim, MD
principal investigator · Princess Margaret Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion